News
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic appoints Erik Lundgren as CEO to lead transition to commercial-stage MS company. Lundgren's extensive biopharmaceutical experience brings strategic and operational expertise to Immunic -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic appoints Michael W. Bonney as Board Chair, bringing over 30 years of biopharmaceutical experience. Bonney led successful commercialization of Avonex® for MS. Exciting plans for future therapies -
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. announces First Quarter 2026 Financial Results and corporate updates including appointment of Michael A. Panzara, M.D., M.P.H. as Chief Medical Officer and progress in ENSURE Trials for MS treatment -
